(S)-(-)-beta-CitronellolCAS# 7540-51-4 |
Quality Control & MSDS
Number of papers citing our products
Chemical structure
| Cas No. | 7540-51-4 | SDF | Download SDF |
| PubChem ID | N/A | Appearance | Oil |
| Formula | C10H20O | M.Wt | 156.2 |
| Type of Compound | Monoterpenoids | Storage | Desiccate at -20°C |
| Solubility | Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc. | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | (S)-(-)-beta-Citronellol may inhibit P-gp-mediated transport and interact with P-gp substrates in the intestinal absorption process. | |||||
(S)-(-)-beta-Citronellol Dilution Calculator
(S)-(-)-beta-Citronellol Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 6.402 mL | 32.0102 mL | 64.0205 mL | 128.041 mL | 160.0512 mL |
| 5 mM | 1.2804 mL | 6.402 mL | 12.8041 mL | 25.6082 mL | 32.0102 mL |
| 10 mM | 0.6402 mL | 3.201 mL | 6.402 mL | 12.8041 mL | 16.0051 mL |
| 50 mM | 0.128 mL | 0.6402 mL | 1.2804 mL | 2.5608 mL | 3.201 mL |
| 100 mM | 0.064 mL | 0.3201 mL | 0.6402 mL | 1.2804 mL | 1.6005 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- Chrysantellin A
Catalog No.:BCN0048
CAS No.:73039-13-1
- 1-Hexanol
Catalog No.:BCN0047
CAS No.:111-27-3
- Englerin A
Catalog No.:BCN0046
CAS No.:1094250-15-3
- Cimiracemoside F
Catalog No.:BCN0045
CAS No.:264875-61-8
- Dhurrin
Catalog No.:BCN0044
CAS No.:499-20-7
- (-)-Hydroxycitric acid lactone
Catalog No.:BCN0043
CAS No.:27750-13-6
- (+)-D-3-Carene
Catalog No.:BCN0042
CAS No.:498-15-7
- Hydroxyvalerenic acid
Catalog No.:BCN0041
CAS No.:1619-16-5
- Cucurbitin chloride
Catalog No.:BCN0040
CAS No.:80546-88-9
- Myrcene
Catalog No.:BCN0039
CAS No.:123-35-3
- 1-Octadecanol
Catalog No.:BCN0038
CAS No.:112-92-5
- Steviol 19-glucoside
Catalog No.:BCN0037
CAS No.:64977-89-5
- Gossypetin 3,3',8-trimethylether
Catalog No.:BCN0050
CAS No.:14965-08-3
- N1,N5,N10-(E)-tri-p-coumaroylspermidine
Catalog No.:BCN0051
CAS No.:364368-18-3
- Miliacin
Catalog No.:BCN0052
CAS No.:5945-45-9
- (S)-(-)-3,7-Dimethyl-6-octenal
Catalog No.:BCN0053
CAS No.:5949-05-3
- 6-Hydroxyflavanone
Catalog No.:BCN0054
CAS No.:4250-77-5
- 2-Nonyl alcohol
Catalog No.:BCN0055
CAS No.:628-99-9
- 3-Ethoxy-4-hydroxybenzaldehyde
Catalog No.:BCN0056
CAS No.:121-32-4
- Hippuric acid
Catalog No.:BCN0057
CAS No.:495-69-2
- Myosmine
Catalog No.:BCN0058
CAS No.:532-12-7
- Apigenin 4'-O-(2'',6''-di-O-E-p-coumaroyl)glucoside
Catalog No.:BCN0059
CAS No.:71781-79-8
- Dihydroxyfumaric acid
Catalog No.:BCN0060
CAS No.:133-38-0
- 4-Isopropylbenzaldehyde
Catalog No.:BCN0061
CAS No.:122-03-2
(R)-(+)-beta-Citronellol and (S)-(-)-beta-Citronellol in Combination with Amphotericin B against Candida Spp.[Pubmed:32150884]
Int J Mol Sci. 2020 Mar 5;21(5). pii: ijms21051785.
The enantiomers (R)-(+)-beta-citronellol and (S)-(-)-beta-Citronellol are present in many medicinal plants, but little is understood about their bioactivity against Candida yeasts. This study aimed to evaluate the behavior of positive and negative enantiomers of beta-citronellol on strains of Candida albicans and C. tropicalis involved in candidemia. The minimum inhibitory concentration (MIC) and minimum fungicide concentration (MFC) were determined. The evaluation of growth kinetics, mechanism of action, and association studies with Amphotericin B (AB) using the checkerboard method was also performed. R-(+)-beta-citronellol and S-(-)-beta-citronellol presented a MIC50% of 64 microg/mL and a MFC50% of 256 microg/mL for C. albicans strains. For C. tropicalis, the isomers exhibited a MIC50% of 256 microg/mL and a MFC50% of 1024 microg/mL. In the mechanism of action assay, both substances displayed an effect on the fungal membrane but not on the fungal cell wall. Synergism and indifference were observed in the association of R-(+)-beta-citronellol and AB, while the association between S-(-)-beta-citronellol and AB displayed synergism, additivity, and indifference. In conclusion, both isomers of beta-citronellol presented a similar profile of antifungal activity. Hence, they can be contemplated in the development of new antifungal drugs providing that further research is conducted about their pharmacology and toxicity.
